Concure Oncology revealed on Friday the addition of Scott Armstrong to its board of directors.
As a member of the company's board, Armstrong supports the advancement of Breast Microseed Treatment as well as continue his advocacy for patient-centric care.
Most recently, Armstrong has served as president and CEO of Group Health Cooperative, anot-for-profit health plan company, positions he has held for 12 years.
Previously at Group Health, Armstrong has worked as VP of Network Services, executive VP/chief administrative officer as well as executive VP/chief operating officer.
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
Aditxt acquires Ignite Proteomics to enhance cancer therapy selection
NASA awards Redwire USD4m to advance drug development in microgravity
Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials